Engineered immune cells take on Hard-to-Treat cervical cancer

NCT ID NCT03362619

Recruiting now Disease control Sponsor: Shenzhen Geno-Immune Medical Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new treatment for people with advanced or recurrent cervical cancer linked to high-risk HPV. The treatment uses specially engineered immune cells (CC-EIEs) designed to target and attack the cancer. Participants receive several infusions of these cells, and researchers monitor safety and whether the tumors shrink or stabilize.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: engineered immune cells (CC-EIEs)
What this could lead to: If successful, this approach could offer a new treatment option for advanced or recurrent cervical cancer that is hard to treat with standard therapies.
What could go wrong: This is an early-phase trial with a small number of participants, so the treatment may not work or could cause significant side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CERVICAL CANCER

Contacts and locations

Locations

Shenzhen Geno-immune Medical Institute
RECRUITING

Shenzhen, Guangdong, 518000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.